Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daclizumab Has Winning Efficacy In MS, But Safety Questions Linger

This article was originally published in The Pink Sheet Daily

Executive Summary

Biogen/Abbott multiple sclerosis candidate passed the relapse rate hurdle and showed surprisingly good disability progression data in the Phase II SELECT trial, but there are safety signals that could be a problem.

You may also be interested in...

Keeping Track: FDA Approval Activity Heats Up With Ocaliva, Zinbryta And More

The latest drug development news and highlights from our FDA Performance Tracker.

U.S. Tysabri Labeling Updated With More PML Risk Info But No Reference To JCV Testing

Partners Biogen Idec and Elan had asked both European and U.S. regulators to update the label to include the addition of anti-JC virus antibody status as a risk factor, but so far only the EU has moved toward JCV testing.

Biogen Idec's BG-12 Results Up The Ante In The Oral MS Market

Biogen's drug is poised to become top dog among many oral MS drugs, including Novartis' approved Gilenya, analysts say.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts